Shots:
- Incyte and Genesis have expanded their collaboration to accelerate the discovery of novel molecules for Incyte-selected targets by deploying Genesis’ GEMS molecular AI platform across a broader range of challenging targets in Incyte’s portfolio
- Incyte will provide experimental data to enhance GEMS’ capabilities, plus the companies will add ≥5 new targets, with options for additional targets over time, while Incyte will have exclusive development & commercialization rights to resulting products
- Genesis will receive $120M upfront, incl. $80M cash & a $40M equity investment, plus recurring research funding and ~$232M per program in milestone payments. The deal could exceed $1B across the 5 initial targets, with additional multi-billion-dollar milestone opportunities for future targets & royalties on approved products
Ref: Businesswire | Image: Incyte & Genesis | Press Release
Related News: Incyte Reports 24-week P-III (TRuE-AD4) Trial Data on Opzelura (Ruxolitinib) Cream in Moderate Atopic Dermatitis (AD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
